Kuwait Trial Targets Muscle Loss During Rapid GLP-1 Weight Reduction
Semaglutide and tirzepatide are changing obesity treatment, but the speed and scale of weight loss have a cost clinicians cannot ignore: lean mass falls along with fat mass. In people with obesity, especially those with type 2 diabetes, shrinking muscle can translate into weaker grip, poorer mobility, and a higher risk of sarcopenia-like functional decline. The LEAN-PREP study is designed around that problem, asking whether two simple add-ons — home-based resistance exercise and higher protein intake — can protect muscle while patients begin semaglutide or tirzepatide therapy.
The trial is being conducted at Dasman Diabetes Institute in Kuwait, where obesity and diabetes carry a heavy clinical burden and where muscle weakness is already common. Investigators are not testing a theoretical concern. They are examining a practical bedside question that has become more urgent as incretin-based therapies produce larger and faster changes in body weight than older treatments ever did.
MRI Quadriceps Area as the Primary Readout
LEAN-PREP is a single-centre, 6-month, randomised controlled trial that will enrol 232 adults with obesity. Participants will be assigned in a 1:1:1:1 ratio to control, resistance exercise, protein supplementation, or the combination of both interventions, all alongside semaglutide or tirzepatide therapy. The main endpoint is MRI-measured quadriceps cross-sectional area, a direct structural marker of muscle preservation that avoids the blind spots of scale weight alone.
The choice of quadriceps imaging is clinically sensible. Quadriceps muscle is central to standing, walking, climbing stairs, and maintaining independence, so a loss here is not just a laboratory finding. It can become a functional event. By anchoring the trial to a muscle-specific imaging endpoint, the investigators are trying to separate healthy fat loss from the unwanted attrition of contractile tissue.
Lean mass loss during major weight reduction often reflects a mix of reduced muscle protein stores, lower mechanical loading, and inadequate dietary intake. A GLP-1 or dual incretin agent can reduce appetite sharply enough that protein consumption falls below what the body needs to maintain muscle. In that setting, resistance exercise provides the missing anabolic signal, while increased protein supplies the substrate for repair and retention.
Home-Based Resistance Training and Higher Protein Intake
The exercise intervention is deliberately pragmatic. Participants assigned to resistance training will perform three home-based sessions per week, beginning with one set and progressing to three sets across major muscle groups. The protocol keeps the intervention feasible for a real-world population rather than confining it to a laboratory-style exercise program that few patients could sustain outside the trial.
Protein supplementation is set to target 1.6 g/kg/day through dietary adjustment and protein products. For a population starting potent anti-obesity therapy, that target is intended to buffer the expected drop in spontaneous caloric intake. It also aligns with the biological rationale for muscle preservation: when appetite suppression reduces total food intake, protein density becomes more important, not less.
One sentence captures the clinical tension here: weight loss is the goal, but muscle loss is not.
The combined arm will test whether exercise and protein act additively or whether one intervention is enough to offset the catabolic pressure that often accompanies drug-induced weight reduction. The study design should also help clarify whether muscle preservation requires both a mechanical stimulus and adequate nutrient delivery, or whether one strategy can carry most of the burden on its own.
Secondary Endpoints Extend Beyond the Muscle
Although quadriceps area is the primary outcome, the secondary measures are broad and clinically relevant. Investigators will assess MRI-measured liver fat content, liver stiffness, and intramuscular fat, along with body composition by dual-energy X-ray absorptiometry. Strength, physical function, dietary intake, physical activity, sleep patterns, quality of life, glycaemic control, and metabolic biomarkers are also included.
Those additional measures matter because obesity is rarely a single-organ problem. A patient may lose weight, improve glucose control, and still struggle with reduced strength or mobility. Likewise, liver fat and intramuscular fat may respond differently from total body weight, and those tissue-level responses can reveal whether the intervention is altering the quality of weight loss, not just its quantity.
A particularly important aspect of this protocol is the inclusion of physical function alongside imaging. Muscle size does not always map perfectly onto performance, especially in populations with diabetes, inactivity, or excess intramuscular fat. By measuring strength and function, the trial acknowledges that muscle preservation has to translate into bedside benefit if it is to change practice.
Why the Kuwait Setting Matters Clinically
Kuwait is not simply the location of convenience for this trial. The protocol is built around a population in which obesity is common and muscle weakness in type 2 diabetes is a major concern. That local burden gives the study immediate relevance for a health system where incretin therapy may be deployed widely and where the unintended consequences of rapid weight loss could be clinically significant.
If the interventions succeed, the implications would be straightforward: clinicians could pair potent obesity pharmacotherapy with structured resistance exercise and higher protein intake from the start, rather than waiting for weakness to emerge. If the trial shows little or no effect, that would be equally useful, because it would suggest that more intensive or differently structured countermeasures are needed to protect muscle during treatment.
Ethical approval was granted by the Dasman Diabetes Institute Ethical Review Committee, and the study is registered at ClinicalTrials.gov under NCT06885736. Written informed consent will be obtained from all participants, and no financial compensation will be provided. Findings are planned for dissemination through peer-reviewed publications and presentations at national and international conferences, with reporting aligned to CONSORT standards.
The protocol does not yet answer whether muscle can be preserved during semaglutide or tirzepatide therapy. It does, however, identify the exact clinical fault line where obesity medicine now sits: larger weight loss is no longer the only outcome that matters, because the tissue being lost may determine whether patients come away healthier or simply smaller.